Double-blind comparison of single-dose alatrofloxacin and cefotetan as prophylaxis of infection following elective colorectal surgery. Trovafloxacin Surgical Group.

Abstract

BACKGROUND:

Alatrofloxacin, the prodrug of trovafloxacin, is a novel fluoroquinolone antimicrobial agent with a broad spectrum, including activity against gram-positive and gram-negative aerobes and anaerobes. Its pharmacokinetic properties (long half-life, excellent tissue distribution, and good safety profile) suggest a role in surgical prophylaxis. This prospective, multicenter, double-blind trial compared alatrofloxacin with cefotetan, an approved drug for surgical prophylaxis, in reducing postoperative infections.

METHODS:

The efficacy and safety of a single 200-mg intravenous dose of alatrofloxacin were compared to a single 2-g intravenous dose of cefotetan in 492 patients undergoing elective colorectal surgery. The efficacy of alatrofloxacin as a prophylaxis for wound, intra-abdominal, or remote-site postoperative infectious complications was compared with cefotetan in 317 clinically evaluable patients; 161 received alatrofloxacin and 156 received cefotetan. The patients were monitored for infections and safety for 30 days postoperatively.

RESULTS:

No statistically significant between-treatment difference was detected in successful clinical response rates at the end of the study (72% for each group). The incidence of primary wound infections at the time of hospital discharge was also similar: 21% in patients treated with alatrofloxacin and 18% in those treated with cefotetan. Safety, established by the incidence of adverse events, did not differ statistically between the groups.

CONCLUSIONS:

A single intravenous dose of alatrofloxacin given within 4 hours prior to surgery was as effective as an intravenous dose of cefotetan in the prevention of postoperative infectious complications in patients undergoing elective colorectal surgery. The safety profiles of the two medications were similar.

• Authors: J W Milsom, D L Smith, M L Corman, R A Howerton, A E Yellin, D R Luke
• Journal: American journal of surgery (Am J Surg) Vol. 176 Issue 6A Suppl Pg. 46S-52S (Dec 1998) ISSN: 0002-9610 [Print] United States
• PMID: 9935257 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Anti-Infective Agents
• Cephamycins
• Fluoroquinolones
• Prodrugs
• alatrofloxacin

Topics

• Adolescent
• Adult
• Aged
• Anti-Infective Agents (administration & dosage, adverse effects)
• Antibiotic Prophylaxis
• Cephamycins (administration & dosage, adverse effects)
• Colon (microbiology, surgery)
• Double-Blind Method
• Elective Surgical Procedures (adverse effects)
• Female
• Fluoroquinolones
• Humans
• Male
• Middle Aged
• Prodrugs (administration & dosage, adverse effects)
• Prospective Studies
• Rectum (microbiology, surgery)
• Surgical Wound Infection (prevention & control)
• Treatment Outcome